Report Highlights
-
The U.S. sales of advanced drug delivery systems were over $54.2 billion in 2004. In 2005 they reached $64.1 billion and will eventually grow to $74.4 billion by the end of 2006. Over 5 years, this market will continue to grow at an average annual growth rate (AAGR) of 15.6% to reach $153.5 billion by 2011.
-
The largest sector of the market consists of sustained release/implants/transdermal drug delivery systems, with more than 50% of the total U.S. market in 2005. Through the forecast period this sector will gradually give way to targeted drug delivery systems, which should control almost 48% of the market in 2011.
-
Targeted drug delivery has the highest growth rate, with a 23.3% AAGR through 2011. The next highest are transmucosal drug delivery systems, with 15.3%.
INTRODUCTION
The drug delivery market is changing drastically due to the introduction of new techniques and routes of delivery. R&D spending, along with increasing competition, new technologies, an international marketplace, and a changing customer base, is creating a new kind of market for drug delivery systems. This study looks at almost all the systems affected by these factors.
This is a very complex market, where many technologies are combined to produce a better delivery system, thus creating niche markets with very specialized applications. The use of liposomes, polymers, etc. in the sustained release oral/injectable drug delivery market is a good example.
Pegylation, nanoparticles, polymers and liposomes are significant new markets. These technologies combined together could be a multibillion dollar global market in the next few years.
Acquisition strategies and collaborations by companies are also covered in this report, e.g., the acquisition of Guilford Pharmaceuticals by MGI Pharma, which added Gliadel Wafer (polifeprosan 20 with carmustine implant) to its portfolio. This study also discusses the strengths and weaknesses of the drug development market in light of new technologies, growing competition and changing customer needs.
SCOPE OF STUDY
This report contains:
- An overview of the major types of drug delivery systems used in the health industry
- Analysis of each technology with an in-depth look at manufacturers, the new products, sales estimates, market projections and market share information
- Discussion of the technological issues, including the latest trends and developments
- Forecasts of the U.S. market and its various sectors, with 5-year projections to 2011
- Profiles of the major players within the industry and a detailed patent analysis.
METHODOLOGY
A comprehensive literature and patent search was conducted. The literature included technical newsletters and journals, as well as many other sources. The data were collected through interviews with leading pharmaceutical and biotech sources. Projections were based on estimates of the current number of end users, potential end users, likely unit prices, rates of consumption and othermarket trends.
INFORMATION SOURCES
BCC surveyed many companies to obtain data for this study. We spoke with officials and consulted newsletters, company literature, product literature, a host of technical articles, journals, indexes, and abstracts. Exhaustive investigations of databases by key terminology were done. In addition, we compiled data from current financial and trade information and from government sources.
ABOUT THE AUTHOR
Shalini Shahani is a young and enterprising scientist and holds a Masters degree in Pharmaceutical Chemistry. Among the research topics she has covered are: Studies on Compounds of Potential and Pharmaceutical Interest from Ibuprofen and 2-Naphthyl Acetic acid. Shahani was awarded a Gold medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S. Some of her other reports with BCC Research are "Medical Imaging Reagents," "Orthopedic Drugs, Implants & Devices," "Reagents of Chromatography", "Spectroscopy, an Enduring Market" and "Advanced Drug Delivery Systems".
Related Reports
Track the Latest Global Tariff Developments
In today's fast-paced global economy, tariffs are no longer static—they are dynamic levers shaped by geopolitical realignments, supply chain vulnerabilities, inflationary pressures, and sustainability-driven trade reforms. As governments worldwide recalibrate their trade strategies, businesses are left to navigate a maze of shifting rules, rising costs, and regulatory uncertainty.
Our analysis empowers you with real-time updates and in-depth expert analysis on all facets of global tariff activity. From new trade agreements and sanctions to abrupt tariff hikes and retaliatory duties, we monitor developments across borders, sectors, and industries—so you don't have to.
Whether it's the ongoing U.S.–China trade dynamics, the evolving EU Carbon Border Adjustment Mechanism (CBAM), or the emerging policies in India, ASEAN, and Latin America, we provide full-spectrum coverage. We also track multilateral trade negotiations, World Trade Organization (WTO) rulings, and sector-specific duty structures—ensuring you are always ahead of global trade shifts.
With our analysis, you can stay informed, identify risks, and confidently respond to tariff changes—no matter where you operate.
Ready to see what tariff means for your business?
Consult with our experts or request your custom Tariff Impact Brife today
Stay Informed, Stay Competitive
In today's interconnected and unpredictable global economy, staying ahead of tariff shifts is not just important—it's essential. BCC Research provides decision-makers with trusted, research-driven insights that turn uncertainty into opportunity.
Our in-depth market analysis and trade intelligence help you decode how tariff changes impact your specific sector—manufacturing, healthcare, technology, agriculture, or energy. We break down complex data into actionable knowledge through comprehensive reports, expert commentaries, and sector-focused forecasts.
Our analysis includes:
- Thorough breakdowns of current and proposed tariff policies and how they affect regional and global trade flows.
- Sector-specific implications, helping you understand the strategic impact on sourcing, pricing, and competitiveness.
- Forward-looking insights to support risk management, planning, and response strategies for evolving trade conditions.
With BCC Research, you gain more than just information—you gain clarity and confidence to make well-informed decisions in a volatile trade environment.
Don't let tariffs catch you off guard—let our insights guide your strategy.
Recent Reports
Global GLP-1 Analogues Market
This report presents detailed information on glucagon-like peptide-1 (GLP-1) analogues. It examines market trends for GLP-1 analogues using data from 2024, estimates for 2025, and projected compound annual growth rates (CAGRs) through 2030 (the forecast period of 2025–2030). The report also covers regional markets for GLP-1 analogues. The GLP-1 analogue market is segmented by route of administration into oral and injection. By region, the market is divided into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America.
Immunotherapy Drugs: Global Markets
The global immunotherapy drugs market is expected to grow from $260.7 billion in 2025 and is projected to reach $467.4 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12.4% during the forecast period of 2025 to 2030.
Global Artificial Intelligence (AI) in Clinical Trials Market
The global market for Artificial Intelligence (AI) in Clinical Trials was valued at $2 billion in 2024 and is estimated to increase from $2.4 billion in 2025 to reach $6.5 billion by 2030, at a compound annual growth rate (CAGR) of 22.6% from 2025 through 2030.
Brain Tumor Therapeutics: Global Markets to 2030
The report provides an analysis of brain tumor therapeutics and analyzes market trends. Using 2024 as the base year, the report provides estimated market data for 2025 through 2030. The market in this report is segmented by therapy type, patient age, end user, and region. The report covers regulatory scenarios, drivers, restraints, opportunities, and the market share for key companies.
Global Viral Vector Manufacturing Markets and Technologies Through 2030
The global market for viral vector manufacturing is expected to grow from $6.3 billion in 2025 and is projected to reach $18.8 billion by the end of 2030, at a compound annual growth rate (CAGR) of 24.6% during the forecast period of 2025 to 2030.
Top Trending Reports
Contract Manufacturing of Medical Devices: Global Markets
The global market for contract manufacturing of medical devices is estimated to grow from $96.4 billion in 2025 to reach $155.2 billion by 2030, at a compound annual growth rate (CAGR) of 10% from 2025 to 2030.
Bioprocess Filtration: Global Markets
The global market for bioprocess filtration is estimated to grow from $8.4 billion in 2025 to reach $15.6 billion by 2030, at a compound annual growth rate (CAGR) of 13.1% from 2025 through 2030.
Global Data Center Market
The global market for data centers is expected to grow from $418.2 billion in 2025 and is projected to reach $691.6 billion by the end of 2030, at a compound annual growth rate (CAGR) of 10.6% during the forecast period of 2025 to 2030.
Biological Therapies for Cancer: Technologies and Global Markets
The global biological therapies market for cancer is expected to grow from $157 billion in 2025 and is projected to reach $225 billion by the end of 2030, at a compound annual growth rate (CAGR) of 7.5% during the forecast period of 2025 to 2030.
Immunotherapy Drugs: Global Markets
The global immunotherapy drugs market is expected to grow from $260.7 billion in 2025 and is projected to reach $467.4 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12.4% during the forecast period of 2025 to 2030.
Report Highlights
- The U.S. market for drug delivery systems in 2002 was $38.8 billion, and is expected to rise at an average annual growth rate (AAGR) of 11.3% and reach $74.5 billion by 2008.
- The sustained release (oral, injectable and topical) dosage form market is rising at an AAGR of 9.7% is expected to reach $34.1 billion by 2008.
- The transmucosal market is expected to grow at an AAGR of 12.8% and reach $17.7 billion by 2008.
- The market for targeted delivery systems was $7.3 billion in 2002 and will reach $15.5 billion by 2008.
- Transdermal systems and implants and IUDs are expected to climb at AAGRs of 11.1% and 12.4%, respectively.
Report Highlights
- Despite the complaints of health care being too expensive, the U.S. pharmaceutical industry is expected to offer increasing opportunities for advanced drug delivery systems, with the U.S. market for the systems estimated at $16.3 billion in 2000. The efficacy, safety, and convenience of the technologies should maintain average annual growth of 10.9% over the next five years, when sales are predicted to be about $27.4 billion.
- At $13.8 billion in estimated 2000 manufacturers' sales, standard controlled release technologies (microencapsulation, polymer/membrane, and coatings) dominate the market for advanced drug delivery systems. The intense competition in generic products is stimulating growth (7.2%), especially in oral formats, both osmotic and microencapsulated. Demand for injected sustained release products is also spurring growth. The widespread interest in controlled released systems should result in sales reaching $19.6 billion in five years.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More